FacebookTwitterLinkedIn
here:scientific-publications:0
Read More

Pharmacokinetic and Pharmacodynamic Bioequivalence between regular human insulin [rDNA origin] in 0.9% sodium chloride ready-to-use infusion 1U/mL and in 100U/mL concentrate diluted to 1U/mL in Healthy Males.

Hompesch M, Hawryluk A, Hernandez M, Uchil B, Wilmington A, Peterson L.
Diabetes Obes Metab. 2021 Aug 10. doi: 10.1111/dom.14520.
here:scientific-publications:1
Read More

TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial.

Loomba R, Mohseni R, Lucas KJ, Gutierrez JA, Perry RG, Trotter JF, Rahimi RS, Harrison SA, Ajmera V, Wayne JD, O'Farrell M, McCulloch W, Grimmer K, Rinella M, Wai-Sun Wong V, Ratziu V, Gores GJ, Neuschwander-Tetri BA, Kemble G.
Gastroenterology. 2021 Jul 20:S0016-5085(21)03276-5. doi: 10.1053/j.gastro.2021.07.025.
here:scientific-publications:2
Read More

Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study.

Hompesch M, Kang J, Han O, Trautmann ME, Sorli CH, Ogbaa I, Stewart J, Morrow L.
BMJ Open Diabetes Res Care. 2021 Jun;9(1):e002208. doi: 10.1136/bmjdrc-2021-002208
here:scientific-publications:3
Read More

Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients.

Baker B, Schaeffler B, Hirman J, Hompesch M, Pederson S, Smith J.
Endocrinol Diab Metab. 2021 Feb 2. doi: 10.1002/edm2.217
here:scientific-publications:4
Read More

Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with NAFLD non-alcoholic fatty liver disease: results from two early phase randomized trials.

Beysen C, Schroeder P, Wu E, Brevard J, Ribadeneira M, Lu W, Dole K, O'Reilly TE, Morrow L, Hompesch M, Hellerstein MK, Li K, Johansson L, Kelly PF.
Diabetes Obes Metab. 2020 Dec 2. doi: 10.1111/dom.14272.
here:scientific-publications:5
Read More

Pharmacokinetic and Dose-Finding Studies on Efpeglenatide in Patients With Type 2 Diabetes

Kun-Ho Yoon, Jahoon Kang, Se Chang Kwon, Michael E Trautmann, Marcus Hompesch, John Stewart, Christopher H Sorli
Diabetes Obes Metab . 2020 Aug;22(8):1292-1301. doi: 10.1111/dom.14032. Epub 2020 Apr 4.
here:scientific-publications:6
Read More

184 Insulin Sensitivity and Glucose Metabolism of Olanzapine and Combination Olanzapine and Samidorphan: A Phase 1 Exploratory Study in Healthy Volunteers

William Martin, Christine Graham, Linda Morrow, Carine Beysen, Frederico G S Toledo, Daiva Bajorunas, Ying Jian, Bernard Silverman, David McDonnell, Mark N Namchuk, John W Newcomer
CNS Spectr . 2020 Apr;25(2):316. doi: 10.1017/S1092852920000991.
here:scientific-publications:7
Read More

Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption

Powell DR, Zambrowicz B, Morrow L, Beysen C, Hompesch M, Turner S, Hellerstein M, Banks P, Strumph P, Lapuerta P
J Clin Endocrinol Metab. 2019 Dec 14. pii: dgz258. doi: 10.1210/clinem/dgz258.
here:scientific-publications:8
See More...
in cat NOT

Stay Connected

Would you like to receive updates from ProSciento?